Navigation Links
The immune system's role in hepatitis C recurrence after liver transplantation
Date:4/1/2009

A new study pinpoints certain aspects of the immune system that may play a role in the recurrence and progression of hepatitis C virus (HCV) after liver transplantation. The study is in the April issue of Liver Transplantation, a journal published by John Wiley & Sons. The article is also available online at Wiley Interscience (www.interscience.wiley.com).

Hepatitis C virus (HCV), which can lead to cirrhosis and liver cancer, is the leading indication for liver transplantation in the U.S. Unfortunately, the infection almost always recurs, and in about 30 percent of cases, it causes cirrhosis in the transplanted liver within five years.

Researchers don't know exactly why some patients fare worse than others, but have been trying to understand the causes. They suspect it is related to the immunological response to HCV which involves natural killer (NK) cells and the killer cell immunoglobulin-like receptors (KIR) which recognize HLA Class I antigens.

Researchers, led by Francesca Poli of Italy, examined the role of KIR genotypes and their HLA ligands in both HCV disease recurrence and its progression after liver transplantation. They retrospectively studied 151 donor-recipient pairs for transplants that occurred between 1991 and 2001. They examined liver biopsies from the recipients that were taken at 1, 3, 5, 7 and 10 years post-transplant to determine when hepatitis recurred, the degree of fibrosis and the progression to cirrhosis.

They found that hepatitis was more likely to recur when the KIR-HLA-C ligands were mismatched between donor and recipient. Also, the presence of KIR2DL3 in the recipient correlated to progression to liver fibrosis.

"Our preliminary data indicates that KIR2DL3 positive recipients would be better assigned a matched donor for the HLA-KIR ligands in order to reduce the risk of developing severe fibrosis after liver transplantation," the authors report.

"In summary," they conclude, "the results presented in this study have shown that disparity for HLA-C allotypes between recipient and donor may increase the risk of recurrence of hepatic inflammation and evidence the importance of the KIR2DL3 receptor in the development of the disease."

They suggest these factors might be considered when selecting an HCV positive liver transplant candidate, to optimize the use of the limited number of organs available.

An accompanying editorial by Lucy Golden-Mason of the University of Colorado says that the study reveals interesting associations and the results could have important implications.

"Identifying variables before liver transplantation that predict more aggressive HCV recurrence is of importance, in particular in the context of donor organ shortage," she concurs.

"Overall," she concludes, "the data supports the model that a genetic component contributes to natural killer cell mediated control of virus as well natural killer cell mediated hepatic injury in the setting of liver transplantation for HCV."


'/>"/>

Contact: Sean Wagner
medicalnews@bos.blackwellpublishing.com
781-388-8550
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. TV crime drama compound highlights immune cells misdeeds
2. Dendritic cells ensure immune tolerance
3. New Study Shows Probiotic Strain Effective in Boosting Immune Response
4. Immune-based drug approved in Europe for pediatric cancer patients
5. Protein helps immune cells to divide and conquer
6. Immune cells from patients with rheumatoid arthritis have prematurely aged chromosomes
7. Immune reaction to metal debris leads to early failure of joint implants
8. Varicella zoster infection causes severe autoimmune hepatitis
9. Frost & Sullivan Lauds Aesku.Diagnostics For Providing an Overall Analysis Platform For a Wide Range of Autoimmune Complications
10. Genetic evidence points to potential therapeutic bypass for autoimmune process
11. German Medical Advancement Reflects Major Improvement in Individuals with Common and Chronic Illnesses Related to Immune System Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... 10, 2016 , ... Dr. Peyman Ghasri, skin doctor ... variety of comprehensive procedures for facial enhancement. The treatments now available at Castle ... and nasal reshaping. , As a result, patients can improve virtually every ...
(Date:2/10/2016)... ... February 10, 2016 , ... Ongoing news of the ravages of ... (ALCA) to conduct a survey that takes a closer look at cases of TBI ... prevalence and causes of TBI among the aging population, and identifies the challenges associated ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... advisory organization, welcomes S.S. Nesbitt as the latest addition to its growing list ... seven other locations throughout the Southeast, from Orlando to Huntsville and in between. ...
(Date:2/10/2016)... ... February 10, 2016 , ... AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology ... quarter and full year ended December 31, 2015 on Monday, February 29, 2016 after ... the investment community following the release at 4:30 PM ET. Investors interested in participating ...
(Date:2/10/2016)... ... February 10, 2016 , ... AHRA: The Association for Medical ... Jan Fox will serve as keynote speaker at the organization’s 2016 Spring Conference. ... to more effectively communicate with their own organizational staff and leadership. , ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ... fourth quarter and full year ended December 31, 2015. ... was a transformational year for Vanda with the continued ... market approval of HETLIOZ for Non-24," said Mihael H. ... Fanapt to our U.S. product portfolio builds on this ...
(Date:2/10/2016)... -- --> --> ... Spectroscopy Market by Industry (Oil & Gas, Petrochemical, Pharmaceutical, Water ... & Mining, and Others), And Geography - Global Forecast ... expected to grow to USD 3.9 Billion by 2020, ... 2020. Browse 82 market data Tables and ...
(Date:2/10/2016)... Feb. 10, 2016  Resolve Therapeutics, LLC, a ... approaches to the treatment of lupus and Sjogrens ... multiple ascending dose study in patients with systemic ... --> --> ... ascending dose study of RSLV-132 in 32 subjects ...
Breaking Medicine Technology: